Author:
Pal Sukumar,Cruz-Fisher Maria I.,Cheng Chunmei,Carmichael Jennifer R.,Tifrea Delia F.,Tatarenkova Olga,de la Maza Luis M.
Abstract
AbstractImplementation of a vaccine is likely the best approach to curtail Chlamydia trachomatis infections. The aim of this study was to determine the ability of a vaccine formulated with the recombinant major outer membrane protein (MOMP) and Th1 and Th2 adjuvants, delivered by combinations of systemic and mucosal routes, to elicit long-term protection in mice against a genital challenge with Chlamydia muridarum. As a negative control, mice were vaccinated with the recombinant Neisseria gonorrhoeae porinB, and the positive control group was immunized with C. muridarum live elementary bodies (EB). The four vaccines formulated with MOMP, as determined by the titers of IgG and neutralizing antibodies in serum, proliferative responses of T-cells stimulated with EB and levels of IFN-γ in the supernatants, elicited robust humoral and cellular immune responses over a 6-month period. Groups of mice were challenged genitally at 60, 120, or 180 days postimmunization. Based on the number of mice with positive vaginal cultures, number of positive cultures, length of time of shedding, and number of inclusion forming units recovered, MOMP vaccinated groups were significantly protected. To assess fertility, when the vaginal cultures became negative, female mice were caged with male mice and the outcome of the pregnancy evaluated. As determined by the number of pregnant mice and the number of embryos, two of the vaccine formulations protected mice up to 180 days postimmunization. To our knowledge this is the first subunit of Chlamydia vaccine that has elicited in mice significant long-term protection against a genital challenge.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference77 articles.
1. Newman, L. et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE 10, e0143304 (2015).
2. CDC. Division of STD Prevention 1–168 (U.S. Department of Health and Human Services, Atlanta, 2019).
3. Schachter, J. & Dawson, C. R. Human Chlamydial Infections. (PSG Publishing Company, Burlington, 1978).
4. Stamm, W. in Sexually Transmitted Diseases (eds. Sparling, P. F. et al.) 575–593 (McGrawHill Book Co., Pennsylvania, 2008).
5. Haggerty, C. L. et al. Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 201, S134–S155 (2010).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献